Myotrophin

Myotrophin®

Mecasermin, rhIGF-1 Neurology A recombinant orphan drug for treating ALS. See Amyotrophic lateral sclerosis.
References in periodicals archive ?
Expression of silicatein and collagen genes in the marine sponge Suberites domuncula is controlled by silicate and myotrophin.
Molecular mechanism of spicule formation in the demosponge Suberites domuncula: silicatein - collagen - myotrophin.
Krasko A, Lorenz B, Batel R, Schroder HC, Muller IM, Muller WE (2000) Expression of silicatein and collagen genes in the marine sponge Suberites domuncula is controlled by silicate and myotrophin.
The acne medicine Myotrophin is believed by some [the studies differ) to reduce the effects of ALS to cells with more efficacy than creatine.
Cephalon, which in June sparked a rally in biotechnology stocks, now joins the ranks of biotechnology disappointments after surprising some investors who bet that its Myotrophin drug would sail smoothly through the FDA approval process, analysts said.
said that results of a nine-month clinical trial of 266 ALS patients showed the drug Myotrophin was the first treatment to slow progression of the disease.
chose UAMS Medical Center as one of eight hospitals to participate in a year-long, second-phase clinical trial of the drug Myotrophin in treatment of patients with amyotrophic lateral sclerosis (Lou Gehrig's disease).
18, 1996 amended complaint, like the claims in the earlier filed complaints, are based on alleged misrepresentations and omissions of material facts concerning Cephalon's North American and European clinical trials of Cephalon's drug, Myotrophin, in the treatment of amyotrophic lateral sclerosis.
4 million related to the co-funding of development expenses and the purchase of certain rights for Myotrophin (insulin-like growth factor) with Cephalon, Inc.
Cephalon's president and chief executive officer, "now that Chiron Corporation has completed its installation of manufacturing facilities in California for potential commercial scale production of Myotrophin with a larger capacity than that available at Beltsville.
NASDAQ:CHIR), announced today that findings from the second Phase III clinical study of Myotrophin(R) (rhIGF-1) reached statistical significance on the primary measure and confirmed previous findings that patients with amyotrophic lateral sclerosis (ALS) who received Myotrophin experienced less disease severity and slower progression of disease compared to patients who received placebo.
10 milligrams per kilogram per day of Myotrophin by subcutaneous injection for up to nine months.